alog_pcfb: Studies of alogliptin for lowering blood glucose...

In MBNMAdose: Dose-Response MBNMA Models

Studies of alogliptin for lowering blood glucose concentration in patients with type II diabetes

Description

A dataset from a systematic review of Randomised-Controlled Trials (RCTs) comparing different doses of alogliptin with placebo \insertCitelangford2016MBNMAdose. The systematic review was simply performed and was intended to provide data to illustrate a statistical methodology rather than for clinical inference. Alogliptin is a treatment aimed at reducing blood glucose concentration in type II diabetes. The outcome is continuous, and aggregate data responses correspond to the mean change in HbA1c from baseline to follow-up in studies of at least 12 weeks follow-up. The dataset includes 14 Randomised-Controlled Trials (RCTs), comparing 5 different doses of alogliptin with placebo, leading to 6 different treatments (combination of dose and agent) within the network.

Usage

alog_pcfb

Format

A data frame in long format (one row per arm and study), with 46 rows and 6 variables:

• studyID Study identifiers

• agent Character data indicating the agent to which participants were randomised

• dose Numeric data indicating the standardised dose received

• y Numeric data indicating the mean change from baseline in blood glucose concentration (mg/dL) in a study arm

• se Numeric data indicating the standard error for the mean change from baseline in blood glucose concentration (mg/dL) in a study arm

• n Numeric data indicating the number of participants randomised

Details

alog_pcfb is a data frame in long format (one row per arm and study), with the variables studyID, agent, dose, y, se, and N.

References

\insertAllCited

MBNMAdose documentation built on Aug. 8, 2023, 5:11 p.m.